Navigation Links
Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Date:1/24/2013

833)(2,717,038)Cash flows from investing activities:  Proceeds from maturity of held-to-maturity investments

5,000,0003,500,000  Proceeds from maturity of available-for-sale investments

3,200,0009,518,252  Purchases of held-to-maturity investments

(2,500,000)(7,640,000)  Purchases of available-for-sale investments

(4,921,036)(3,046,270)  Purchases of property, plant and equipment

(137,101)(222,826)  Proceeds from sale of property, plant and equipment

7,038-  Purchase of intangible assets

(4,440)(77,738)Net cash provided by investing activities

644,4612,031,418Cash flows from financing activities:  Net proceeds from exercise of options

150,000208,825Net cash provided by financing activities

150,000208,825Effect of exchange rate changes on cash and cash equivalents

(6,313)(26,208)Net increase (decrease) in cash and cash equivalents

156,315(503,003)Cash and cash equivalents at beginning of period

4,653,2266,063,573Cash and cash equivalents at end of period

$4,809,541$5,560,570Cash paid during the period for interest

$12$57Cash paid during the period for income taxes

42,31931,307 

Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
2. Uroplasty To Participate In Two Upcoming Investor Conferences
3. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
4. Uroplasty To Participate In Two Upcoming Conferences
5. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
6. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
7. Uroplasty To Present At The JMP Securities Healthcare Conference
8. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
9. Uroplasty Announces Product Development and New Clinical Trial Initiatives
10. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
11. Cepheid Reports Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Morria Biopharmaceuticals Plc, a,biopharmaceutical company focused ... announced that it has obtained regulatory,approval from ... to initiate,a Phase II study of MRX-4 ... The two-arm, randomized, multi-dose, double-blind, placebo-controlled,study includes ...
... Md., June 11 EntreMed, Inc.,(Nasdaq: ENMD ... treatment of cancer and inflammatory diseases, today,announced the ... of 2-,methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter,and ... for analogs,of 2ME2 in oncology and a broad ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated ... national survey by researchers at the University of Michigan ... under the age of 18 at home, and adults ... than other adults to support universal coverage of birth ... the Journal of the American Medical Association ...
(Date:4/22/2014)... has been approved since November 2013 for the prevention ... In an early benefit assessment pursuant to the "Act ... (AMNOG), the German Institute for Quality and Efficiency in ... offers an added benefit over the appropriate comparator therapy. ... of turoctocog alfa is not proven. As no relevant ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
Breaking Medicine News(10 mins):Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... of a multi-faceted transcriptional complex to control of ... stem cells. Two separate studies, published by Cell ... Cell, provide insight into novel subunits associated with ... a previously undescribed chromatin function that is required ...
... M.D., Will Lead One of the Nation,s Largest ... Electrophysiology Programs, ... and Director of Cardiac Electrophysiology at,Washington University in St. Louis, has ... Institute., "We are pleased to have such an established leader ...
... largest,provider of business services to orthodontic and dental ... and Atlanta, Georgia to,better serve the company,s practices ... confirm our operating principle that the,heart of our ... in the,hundreds of practices we serve each day," ...
... 11% of international disease burden , , THURSDAY, Jan. 17 ... childhood malnutrition accounts for more than one-third of childhood ... researchers report. , "The key messages here are that ... reform is needed," lead researcher Dr. Robert Black, a ...
... adopt the World Health Organization (WHO) standard on fine particulate ... premature deaths, concludes research in the Journal of Epidemiology and ... levels of fine particulate matter pollution (PM2.5) at 20 g/m ... by the US Environmental Protection Agency is 15 g/m ...
... London, New Delhi and Singapore (January 17, 2008) ... looks set to continue its successful growth in ... partnership with the International Union for Health Promotion ... Promotion & Education. , Published quarterly, Promotion and ...
Cached Medicine News:Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3Health News:Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology 2Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 3Health News:Europe should adopt WHO recommendations for particulate matter cuts 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: